Shukun Technology Bags ￥200M in New Round of Financing

According to PEdaily.cn, on August 31, 2020, Shukun Technology announced the completion of a new round of financing of 200 million yuan, led by Qiming Venture Partners, with additional support from Thunder Software, Everest Venture Capital and SPD Silicon Valley Bank. In June 2020, Shukun Technology also raised ￥200 million in Series B2 financing. Proceeds from the latest round will be used to expand the business of Shukun Technology in the AI-based medical imaging market and accelerate the improvement and commercialization of more AI-powered medical products.

Founded in June 2017 and headquartered in Beijing, Shukun Technology began to explore the application of AI technology in healthcare and started to do researches on cardiovascular diseases. 

In July 2020, Shukun Technology launched the "digital brain" product family. "Digital brain" covers all scenarios of stroke imaging. It can accurately locate lesions, provide image-assisted diagnosis including related parameters of bleeding, ischemia, aneurysm, and CTP, and shorten the time of emergency treatment. At present, the products of the "digital brain" have been used in more than 100 hospitals across the country.

Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Shenzhen, Hong Kong, Seattle, Boston, and San Francisco Bay Area. Currently, Qiming Venture Partners manages seven US Dollar funds and five RMB funds with over US$4 billion assets under management. Qiming Venture Partners invests in information technology, new consumer business patterns, and the healthcare sector.

Everest Venture Capital has always been committed to its vision of investing in 100 world-class high-tech firms. Founded by Mr. XIAO Jiancong and his team in September 2007, the company now has a 140-strong workforce. The company has over RMB 7 billion in AUM. 

So far, Everest Venture Capital has invested in over 150 companies, with a focus on high-tech fields such as high-end equipment, new materials, bio-pharmaceuticals and the new generation of information technology.